Enhanced Liver Fibrosis Panel (ELF)

The Enhanced Liver Fibrosis (ELF) test is a diagnostic test that evaluates the extent of liver fibrosis and assesses the progression of liver disease. It measures specific biomarkers in the blood that are associated with liver fibrosis - Hyaluronic Acid, Amino-terminal Propeptide of Type III collagen (PIIINP), and Tissue Inhibitor of Matrix Metalloproteinase 1 (TIMP-1). This test provides valuable information about a patient's liver health. The ELF panel is a non-invasive alternative to liver biopsy, allowing for early detection and monitoring of liver fibrosis.

Chronic Liver Disease is one of the leading causes of death globally. Significant contributors include Viral Hepatitis B and C, Alcoholic Liver Disease, and Non-Alcoholic Fatty Liver Disease. Management of patients with CLD requires assessment and staging of fibrosis to identify those who are at the most risk and in need of treatment or lifestyle modification.

The symptoms of liver fibrosis include:

• Fatigue
• Abdominal pain or discomfort
• Jaundice (yellowing of the skin and eyes)
• Swelling in the legs and ankles
• Unexplained weight loss
• Nausea and vomiting
• Loss of appetite

The ELF panel requires a blood sample for testing. The sample is obtained through a simple blood draw, usually from a vein in the arm. The procedure is quick and relatively painless. It is important to follow any fasting instructions provided by your healthcare provider, as it may affect the accuracy of the test results.

Once the blood sample is collected, it is sent to a laboratory for analysis. The ELF panel measures three biomarkers - hyaluronic acid, PIIINP, and TIMP-1. These biomarkers are indicative of liver fibrosis and allow for the assessment of its stage and severity. The results are analysed and interpreted by experienced professionals, providing a comprehensive evaluation of liver fibrosis.

In the case of a positive diagnosis of liver fibrosis, it is important to identify and address the underlying cause of the liver disease. Treatment options may vary depending on the specific condition or disease causing the fibrosis. These can include lifestyle changes, medication, or, in some cases, surgical intervention. It is crucial to work closely with a healthcare provider to develop an individualised treatment plan.

The benefits of an early diagnosis include the following:

• Early detection allows for timely intervention, potentially slowing down the progression of liver fibrosis.
• Knowledge of liver fibrosis can help individuals make necessary lifestyle changes and take steps to improve their liver health.
• Prompt treatment can prevent further complications and improve overall quality of life.

Getting tested on Apollo 24|7 is quick and convenient. Simply visit the Apollo 24|7 website or mobile app, search for the Enhanced Liver Fibrosis Panel (ELF), and book your convenient time and date slot at a nearby diagnostic centre. The test can be done at your convenience without the need for a doctor's prescription. Once the sample is collected, you can expect to receive your test results within 7 days.